Helium Advisors LLC Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Helium Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,335 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Brighton Jones LLC increased its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC increased its position in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Bryce Point Capital LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $497,000. Arete Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 8.2% in the fourth quarter. Arete Wealth Advisors LLC now owns 16,955 shares of the company’s stock worth $2,444,000 after acquiring an additional 1,290 shares in the last quarter. Finally, Atlas Capital Advisors Inc. increased its position in shares of Johnson & Johnson by 9,344.3% in the fourth quarter. Atlas Capital Advisors Inc. now owns 5,761 shares of the company’s stock worth $833,000 after acquiring an additional 5,700 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.6%

Johnson & Johnson stock opened at $167.33 on Friday. The firm’s 50-day moving average is $157.46 and its 200-day moving average is $156.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market cap of $402.99 billion, a P/E ratio of 17.90, a PEG ratio of 2.10 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm posted $2.82 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JNJ. UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Royal Bank Of Canada increased their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Raymond James Financial decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.